| Literature DB >> 34635614 |
Bongyoung Kim1, Jin-Hong Kim2, Yangsoon Lee2.
Abstract
BACKGROUND: Extraintestinal pathogenic Escherichia coli (ExPEC) causes various infections, including urinary tract infection (UTI), sepsis, and neonatal meningitis. ExPEC strains have virulence factors (VFs) that facilitate infection by allowing bacterial cells to migrate into and multiply within the host. We compared the microbiological characteristics of ExPEC isolates from blood and urine specimens from UTI patients.Entities:
Keywords: Escherichia coli; ST131; Urinary tract infection; Virulence factors; Whole-genome sequencing; tsh
Mesh:
Substances:
Year: 2022 PMID: 34635614 PMCID: PMC8548248 DOI: 10.3343/alm.2022.42.2.203
Source DB: PubMed Journal: Ann Lab Med ISSN: 2234-3806 Impact factor: 3.464
Clinical factors possibly influencing the culture results of blood and urine specimens
| Clinical factor (%) | Blood (N=40) | Urine (N=40) |
|
|---|---|---|---|
| Age, median (IQR) | 72.5 (59–81) | 70 (54.5–78.5) | 0.473 |
| Male sex, N (%) | 4 (10.0) | 2 (5.0) | 0.675 |
| Time lag between fever or UTI symptom onset and bacterial culture sampling, days, median (IQR) | 2 (1–3.75) | 1 (0–4) | 0.382 |
| History of antibiotic use within three days prior to bacterial culture sampling | 8/39 (20.5) | 7 (17.5) | 0.733 |
| Antimicrobial use concordant with the antimicrobial susceptibility of the causative organisms | 3/39 (7.7) | 1 (2.5) | 0.359 |
| Existence of any underlying urinary tract abnormalities | 18 (45.0) | 17 (42.5) | 0.822 |
| Benign prostatic hypertrophy among male patients | 1/4 (25.0) | 2/2 (100) | 0.400 |
| Neurogenic bladder | 1 (2.5) | 2 (5.0) | 1.000 |
| Urolithiasis | 12 (30.0) | 5 (12.5) | 0.056 |
| Urinary retention | 0 (0) | 1 (2.5) | 1.000 |
| Vesicoureteral reflux | 0 (0) | 0 (0) | - |
| Bladder diverticulum | 0 (0) | 1 (2.5) | 1.000 |
| Prolapse of vagina among female patients | 0 (0) | 0 (0) | - |
| Intubated urinary tract at the time of culture sampling | 5 (12.5) | 9 (22.5) | 0.239 |
| Intermittent catheterization | 0 (0) | 2 (5.0) | 0.494 |
| History of urinary catheterization during one month prior to inclusion | 4 (10.0) | 3 (7.5) | 1.000 |
| Polycystic kidney | 0 (0) | 0 (0) | - |
| Kidney tumor | 0 (0) | 1 (2.5) | 1.000 |
| Urinary tract surgery during three months prior to inclusion | 2 (5.0) | 1 (2.5) | 1.000 |
| Surgically reconstructed bladder | 0 (0) | 0 (0) | - |
Abbreviations: IQR, interquartile range; UTI, urinary tract infection.
Number of isolates (%) according to MLST in blood and urine specimens
| ST- | Blood (N=40) | Urine (N=40) |
|
|---|---|---|---|
| ST131 | 8 (20) | 11 (28) | 0.431 |
| ST131- | 6 (15) | 8 (0.556) | 0.556 |
| ST131- | 2 (5) | 2 (1.000) | 1.000 |
| ST131- | 0 (0) | 1 (0.314) | 0.314 |
| ST95 | 9 (23) | 7 (18) | 0.576 |
| ST95- | 6 (15) | 3 (0.288) | 0.288 |
| ST95- | 1 (3) | 1 (1.000) | 1.000 |
| ST95- | 2 (5) | 2 (1.000) | 1.000 |
| ST95- | 0 (0) | 1 (0.314) | 0.314 |
| ST69- | 8 (20) | 3 (8) | 0.105 |
| ST1193 | 4 (10) | 5 (13) | 0.723 |
| ST1193- | 3 (8) | 4 (0.692) | 0.692 |
| ST1193- | 1 (3) | 1 (1.000) | 1.000 |
| ST73 | 3 (8) | 2 (5) | 0.644 |
| ST12 | 0 (0) | 4 (10) | 0.040 |
| ST38 | 1 (3) | 2 (5) | 0.556 |
| ST127 | 0 (0) | 2 (5) | 0.152 |
| ST357 | 1 (3) | 1 (3) | 1.000 |
| Others | 6 (15) | 3 (8) | 0.288 |
*Nine isolates belonging to ST10, ST14, ST70, ST372, ST394, ST421, ST457, ST998, and ST2613.
Abbreviations: ST, sequence type; MLST, multilocus sequence type.
Antimicrobial resistance rates (%) according to ST and specimen type
| Antimicrobial agent | ST (N of isolates) | Specimen type (N isolates) | |||||
|---|---|---|---|---|---|---|---|
| ST131 (19) | ST95 (16) | ST69 (11) | ST1193 (9) | Others (25) | Blood (40) | Urine (40) | |
| Ampicillin |
| 31.3 |
|
|
|
|
|
| Piperacillin |
| 31.3 |
|
|
|
|
|
| Cefoxitin | 0 | 0 | 0 | 11.1 | 4.0 | 0 | 5.0 |
| Ceftazidime |
| 6.3 | 0 | 0.0 | 12.0 | 20.0 | 27.5 |
| Cefotaxime |
| 6.3 | 0 | 11.1 | 12.0 | 20.0 | 30.0 |
| Cefuroxime |
| 6.3 | 9.1 | 11.1 | 12.0 | 22.5 | 30.0 |
| Aztreonam |
| 6.3 | 0 | 11.1 | 12.0 | 22.5 | 27.5 |
| Cefepime |
| 6.3 | 0.0 | 0.0 | 12.0 | 20.0 | 27.5 |
| Ampicillin/sulbactam | 31.6 | 12.5 |
|
|
| 40.0 | 45.0 |
| Amoxicillin/clavulanate | 26.3 | 0.0 | 9.1 | 11.1 | 12.0 | 2.5 | 22.5 |
| Piperacillin/tazobactam | 5.3 | 0 | 9.1 | 0 | - | 2.5 | 2.5 |
| Doripenem | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ertapenem | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Meropenem | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Imipenem | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Amikacin | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gentamicin | 47.4 | 0 | 27.3 | 22.2 | 16.0 | 25.0 | 20.0 |
| Tobramycin |
| 0.0 | 27.3 | 22.2 | 8.0 | 22.5 | 20.0 |
| Trimethoprim/sulfamethoxazole |
| 12.5 | 45.5 | 33.3 | 40.0 | 42.5 | 32.5 |
| Ciprofloxacin |
| 6.3 | 9.1 |
| 8.0 | 30.0 | 37.5 |
| Levofloxacin |
| 0 | 0 |
| 8.0 | 22.5 | 37.5 |
| Chloramphenicol | 0 | 6.3 | 0 | 0.0 | 8.0 | 2.5 | 5.0 |
| Fosfomycin | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tetracycline |
| 12.5 | 18.2 | 33.3 | 32.0 | 30.0 | 35.0 |
| Minocycline | 0 | 0 | 0 | 11.1 | 16.0 | 5.0 | 7.5 |
| Tigecycline | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Colistin | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ESBL positive |
| 6.3 | 0 | 0 | 12.0 | 20.0 | 27.5 |
Resistance rates >50% are indicated in bold.
Abbreviations: ST, sequence type; ESBL, extended-spectrum β-lactamase.
Antimicrobial resistance mechanisms of ESBL-producing and fluoroquinolone-resistant isolates according to ST-fimH-serotype
| ST- | Antimicrobial resistance mechanism | N isolates | |||
|---|---|---|---|---|---|
| ESBL gene | QRDR variation in | ||||
|
|
|
| |||
| ST131- | CTX-M-15 | S83L, D87N | S80I, E84V | I529L | 8 |
| CTX-M-14, 27 | S83L, D87N | S80I, E84V | I529L | 2 | |
| CTX-M-55 | S83L, D87N | S80I, E84V | I529L | 2 | |
| - | S83L, D87N | S80I, E84V | I529L | 1 | |
| ST131- | CTX-M-27 | S83L | - | I529L | 2 |
| ST131- | CTX-M-27 | S83L, D87N | S80I, E84V | I529L | 1 |
| ST95- | CTX-M-14 | - | - | - | 1 |
| ST95- | - | S83L, D87Y | S80R | - | 1 |
| ST38- | CTX-M-14 | S83L, D87Y | S80I | S458A | 1 |
| ST38- | - | S83L, D87N | S80I, E84V | - | 1 |
| ST457- | CTX-M-14 | - | - | - | 1 |
| ST12- | DHA-1 | - | - | - | 1 |
| ST1193- | - | S83L, D87N | S80I | L416F | 5 |
| - | S83L, D87N | - | - | 2 | |
| ST1193- | - | S83L, D87N | S80I | L416F | 1 |
| - | S83L, D87N | - | - | 1 | |
| ST69- | - | S83L, D87N | S80I | - | 1 |
Abbreviations: ESBL, extended-spectrum β-lactamase; QRDR, quinolone resistance-determining region; -, not detected; ST: sequence type.
Proportions (%) of VFs according to ST and specimen type
| VF | VF gene | ST (N isolates) | Specimen type (N isolates) | Total (80) | |||||
|---|---|---|---|---|---|---|---|---|---|
| ST131 (19) | ST95 (16) | ST69 (11) | ST1193 (9) | Others (25) | Blood (40) | Urine (40) | |||
| Adherence | |||||||||
|
| 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| Hemorrhagic |
| 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EaeH |
| 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Type I fimbriae |
| 100 | 100 | 91 | 100 | 100 | 100 | 100 | 100 |
| P fimbriae |
| 95 | 94 | 64 | 100 | 80 | 85 | 88 | 86 |
| F1C fimbriae |
| 0 | 0 | 0 | 0 | 52 | 13 | 20 | 16 |
| Afimbrial adhesin AFA-I | 16 | 6 | 9 | 0 | 32 | 18 | 15 | 16 | |
| S fimbriae |
| 0 | 0 | 0 | 0 | 40 | 10 | 15 | 13 |
| AAF/II fimbriae |
| 21 | 0 | 9 | 0 | 8 | 15 | 3 | 9 |
|
| 0 | 0 | 0 | 0 | 24 | 8 | 8 | 8 | |
| CFA/I fimbriae |
| 0 | 0 | 0 | 0 | 16 | 5 | 5 | 5 |
| AAF/III fimbriae |
| 0 | 0 | 0 | 0 | 4 | 0 | 3 | 1 |
| K88 fimbriae |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Curli fibers | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| EtpA |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dispersin |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intimin |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Porcine attaching-effacing associated protein |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ToxB |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Autotransporters | |||||||||
| UpaG adhesin, trimeric AT |
| 95 | 100 | 100 | 100 | 88 | 95 | 95 | 95 |
| EhaB, AIDA-I type |
| 89 | 88 | 100 | 100 | 88 | 93 | 90 | 91 |
| Antigen 43, AIDA-I type |
| 89 | 69 | 45 | 100 | 60 | 70 | 73 | 71 |
| Temperature-sensitive hemagglutinin |
| 100 | 6 | 0 | 100 | 32 | 40 | 53 | 46 |
| Sat |
| 79 | 0 | 55 | 89 | 32 | 55 | 38 | 46 |
| Vacuolating autotransporter gene |
| 0 | 81 | 9 | 44 | 68 | 45 | 43 | 44 |
| Cah, AIDA-I type |
| 63 | 38 | 18 | 0 | 44 | 35 | 43 | 39 |
| EspC, SPATE |
| 100 | 6 | 0 | 0 | 16 | 25 | 35 | 30 |
| Enteroaggregative immunoglobulin repeat protein |
| 0 | 0 | 100 | 0 | 24 | 28 | 15 | 21 |
| Contact-dependent growth inhibition system |
| 11 | 0 | 0 | 0 | 48 | 10 | 25 | 18 |
| UpaH, AIDA-I type |
| 0 | 0 | 9 | 33 | 12 | 10 | 8 | 9 |
| Pic |
| 0 | 0 | 0 | 0 | 24 | 13 | 3 | 8 |
| AIDA-I |
| 11 | 0 | 0 | 0 | 0 | 5 | 0 | 3 |
| EhaA, AIDA-I type |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EspI, SPATE |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pet, SPATE |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AIDA-I type |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AatA, AIDA-I type |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EspP |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Invasion | |||||||||
| Invasion of brain endothelial cells |
| 0 | 0 | 0 | 0 | 16 | 5 | 5 | 5 |
| Tia/Hek |
| 53 | 88 | 18 | 0 | 68 | 53 | 55 | 54 |
| Iron uptake | |||||||||
| Iron/manganese transport |
| 100 | 100 | 100 | 100 | 92 | 98 | 98 | 98 |
| Heme uptake |
| 100 | 100 | 91 | 100 | 96 | 98 | 98 | 98 |
| Yersiniabactin siderophore |
| 100 | 100 | 91 | 100 | 100 | 98 | 100 | 99 |
| Aerobactin siderophore |
| 74 | 44 | 73 | 89 | 52 | 73 | 53 | 63 |
| Iron-regulated element |
| 5 | 88 | 18 | 0 | 44 | 40 | 30 | 35 |
| Salmochelin siderophore |
| 5 | 13 | 27 | 0 | 68 | 28 | 30 | 29 |
| Toxins | |||||||||
| Hemolysin/cytolysin A |
| 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Colicin-like Usp |
| 100 | 100 | 0 | 100 | 72 | 73 | 83 | 78 |
| Enterotoxin SenB/TieB |
| 79 | 38 | 45 | 56 | 52 | 53 | 58 | 55 |
| Alpha-hemolysin |
| 53 | 0 | 27 | 0 | 60 | 28 | 43 | 35 |
| Cytotoxic necrotizing factor 1 |
| 53 | 0 | 0 | 0 | 48 | 20 | 35 | 28 |
| Cytolethal distending toxin |
| 0 | 0 | 0 | 0 | 4 | 0 | 3 | 1 |
| Shiga-like toxin |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Heat-labile enterotoxin |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Heat-stable enterotoxin 1 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Enterotoxin 1 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Abbreviations: ST, sequence type; VF, virulence factor; CFA, colonization factor antigen; AAF, aggregative adhesion fimbria; SPATE, serine protease autotransporters of Enterobacteriaceae; sat, secreted autotransporter toxin; AIDA, adhesin involved in diffuse adherence.
Fig. 1Box plot with median and interquartile range of virulence scores according to ST. Virulence scores were calculated based on the number of VFs present and compared using the Kruskal–Wallis test.
Abbreviations: ST, sequence type; VF, virulence factor.